kainos loboratories,inc (4556) Cash flow
Market cap
¥10.4B
P/E ratio
16x
Kainos manufactures diagnostic pharmaceuticals, laboratory reagents, and medical devices for hospitals and research facilities to improve healthcare quality.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 136 | 143 | 133 | 110 | 134 | 136 | 143 | 150 | 142 | 119 | 103 | 103 |
| Cash from operations | 393 | 301 | 373 | 338 | 425 | 678 | 591 | 604 | 545 | 431 | 705 | 554 |
| Capital expenditures | -36 | -159 | -70 | -57 | -68 | -12 | -73 | -141 | -8 | -74 | -71 | -5 |
| Cash from investing | -41 | -161 | -70 | -266 | -20 | -52 | -117 | -141 | -10 | -73 | -71 | -27 |
| Payments for dividends | -34 | -56 | -55 | -56 | -56 | -60 | -67 | -66 | -112 | -111 | -142 | -156 |
| Repurchases of common stock | -0 | -266 | -51 | - | -541 | - | -90 | -158 | -0 | - | - | - |
| Proceeds from issuance of term debt, net | 200 | 300 | 100 | 200 | 300 | 100 | 200 | 300 | 100 | 150 | 300 | - |
| Repayments of term debt | -200 | -300 | -100 | -200 | -300 | -100 | -200 | -300 | -100 | -200 | -300 | -100 |
| Cash from financing | -168 | -345 | -241 | -77 | -648 | 386 | -195 | -31 | -191 | -204 | -411 | -182 |